Intra-aortic balloon counterpulsation: rationale, application and results.
Intra-aortic balloon counterpulsation is an effective means of reducing myocardial ischemia and supporting the failing circulation. Its therapeutic benefits are the direct result of distolic augmentation and systolic unloading, the former increasing myocardial perfusion and the latter enhancing cardiac performance. Indirect effect include diminution of ischemia by decrease in the determinants of myocardial oxygen demand and improved ventricular function secondary to the decreased ischemia. Intra-aortic balloon counterpulsation is indicated in clinical syndromes related to intractable cardiac ischemia, including myocardial infarction shock and severe left ventricular failure, refractory ischemic pains, and ventricular arrhythmias unresponsive to medical management. It is also of importance in other situations associated with low cardiac output. This therapeutic modality has recently been considered for early use in extensive myocardial infarction to limit cardiac damage and avert complications. Recent technical advances have facilitated the ease and safety of application of intra-aorta balloon counterpulsation. Complication are of low frequency but can be serious and employment of the method is predicated upon consideration of both potential benefits and risks.
D000208:Acute Disease; D000787:Angina Pectoris / Q000628:therapy; D001145:Arrhythmias, Cardiac / Q000628:therapy; D001243:Assisted Circulation; D003326:Coronary Circulation; D003327:Coronary Disease / Q000188:drug therapy / Q000503:physiopathology* / Q000628:therapy; D006321:Heart / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D007423:Intra-Aortic Balloon Pumping / Q000009:adverse effects / Q000379:methods; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality; D009206:Myocardium / Q000378:metabolism; D012770:Shock, Cardiogenic / Q000628:therapy; D013577:Syndrome; D014665:Vasodilator Agents / Q000627:therapeutic use
D014665:Vasodilator Agents